Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-JIA
2025-520923-25-00Phase 3Authorised
- Sponsor
- Duke Clinical Research Institute
- Start
- Jun 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, open-label trial of adalimumab, etanercept, abatacept, tocilizumab and tofacitinib in juvenile idiopathic arthritis (JIA) (3 arms), sponsored by Duke Clinical Research Institute. Primary endpoint: Minimal disease activity at Month 6. Planned start Jun 2026; status: authorised.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2025-520923-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520923-25-00.